Biblio
Bispecific CAR T cell therapy targeting BCMA and CD19 in relapsed/refractory multiple myeloma: a phase I/II trial. Nat Commun. 2024;15(1):3371.
Caspase-1 inhibition ameliorates murine acute graft versus host disease by modulating the Th1/Th17/Treg balance. Int Immunopharmacol. 2021;94:107503.
Coagulation Disorders after CAR T Cell Therapy: Analysis of 100 Patients with R/R Hematologic Malignancies. Biol Blood Marrow Transplant. 2019.
A combination of pre-infusion serum ferritin, CRP and IL-6 predicts outcome in relapsed/refractory multiple myeloma patients treated with CAR-T cells. Front Immunol. 2023;14:1169071.
. .